Tepotinib plus an EGFR tyrosine kinase inhibitor in patients with EGFR-mutant MET-altered NSCLC: A case series

• Case series of tepotinib plus EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC.
• Clinical benefit (23/25) and favorable safety shown in these heavily pretreated patients.
• These combinations provide a potential chemotherapy-sparing, oral therapy option.

• No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung cancer (NSCLC) and MET-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
• This case series describes real-world outcomes with tepotinib, a selective MET-TKI, in combination with EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC and resistance to EGFR-TKIs.
• Among the 25 patients included, tepotinib was given in combination with a range of EGFR-TKIs (osimertinib, n = 18; gefitinib, n = 5; dacomitinib, n = 1; afatinib, n = 1) as second (n = 8), third (n = 9), or fourth-or-later (n = 8) line therapy.
• Tepotinib plus EGFR-TKIs demonstrated clinical benefit per physician’s assessment in 23/25 patients, with a partial response in 15/25 patients.
• Tepotinib plus EGFR-TKIs showed favorable tolerability that was consistent with previous observations, with edema reported as the most common tepotinib-related adverse event (14/25 patients).
• This case series, including patients with several prior treatment lines, suggest tepotinib plus an EGFR-TKI as a potential chemotherapy-sparing, oral targeted treatment option for patients with EGFR‑mutated, MET-altered NSCLC after progression on EGFR‑TKIs.

Read more.